Email Facebook Twitter

RNS VIDEO: Reabold Resources #RBD raise £6 million and take stake in Danube Petroleum Watch here

EXCLUSIVE: HemoGenyx are creating blood cancer treatments with US$9 billion market potential

Member Info for inanaco

Premium Member

Send a private message to inanaco

Member Since: Wed, 19th Oct 2011

Number of Share Chat Posts (all time): 25,497
Number of Share Chat Posts (last 30 days): 265

Last Posted: Today 17:20

Post Distribution over the last 30 days

Today 17:20

proof as ever will be who takes it further and at what price ... is the decider ...
Today 17:17

Mathsprof, your very much aware so many things influence patient outcome, immune system, strength, age etc etc, so you need big trials to prove OS when 60% of the patients are within this 100 day interval period. with 7 patients ,1 patient can have a huge influence on the P value even if you accepted the comparative data as true, Big Pharma will run 1000 patient trials to prove 100 days .... never seen 7
Today 16:51

which is exactly what i have stated, John ... ""low numbers"" are not going to give you efficacy results against an unknown control group which would be acceptable evidence .. because you can dress them up in anyway you want.

I will leave it with you ATB
Today 16:39

your more than welcome to chap, trials are multi center UK based,with the latest announcement that Cancer Research itself will fund trials, also a trial will be submitted early 2018 in the US .. as such these discussions would not occur
Today 16:35

John, find an actual placebo control arm or the actual trial for the chemo that VAL used that would give you precise data
on OS as a guideline
Today 16:30

actually i am not disproving VAL ... or the data, its if you can trust it ? i am afraid that is not up to VAL, its up to who ever is going to fund this program ... further fundraising for a phase 3 trial ? big Pharma or some other means. To do that you have to convince them, can call me devils advocate if you wish ... but i am not saying buy, sell hold or any forecast, maybe the 201 data is far more conclusive ... who knows as its not published yet
Today 16:23

the treatment appears safe C7, that's not the issue, what folks need to do is prove the comparative arm is fair, because its not controlled and using just 7 treated patients is way to small a number when your trying to prove extended survival because patient's are not clones,
Today 16:12


"""Comparing the OS rates of treated patients to untreated patients and measuring from the date that patients received their first course of chemotherapy for non-small cell lung cancer until the date of death, VAL401 treatment provides a statistically significant (p = 0.0109 log likelihood ratio) improvement in survival.""""

does say Date of death ....
Today 16:07

this is not about value of SP or value of the data presented to you by the BOD

its about the value of the Data to Big Pharma or EU / FDA ......

or is your market Georgia ? with a population of 3.7m people

Sign up for Live Prices
Top Recommended
Hot Chat Topics
Top recommended posters in the last 30 days

Member Login

Forgotten your password?


Don't have an account? Click here to Register Free!

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.